More on VYGR
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.10 |
|
|||
| Open | $3.11 | ||||
| 52 Wk High | $30.54 | ||||
| 52 Wk Low | $8.12 | ||||
| Day High | $3.28 | ||||
| Day Low | $3.02 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 713,223 | ||||
- H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR)
- Form 8-K Voyager Therapeutics, For: Jul 13
- Voyager tau gene therapy shows tolerability in 6-month NHP study
- Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
- Voyager to present Alzheimer's gene therapy data at AAIC 2026
- Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
- Form 4 Voyager Therapeutics, For: Jun 09 Filed by: SCANGOS GEORGE A
- Form 4 Voyager Therapeutics, For: Jun 09 Filed by: MACKEY CATHERINE J
- Form 4 Voyager Therapeutics, For: Jun 09 Filed by: Hyman Steven
- Form 4 Voyager Therapeutics, For: Jun 09 Filed by: Vitale Nancy
Entities mentioned with VYGR
- Genzyme/Sanofi-Aventis | View Related Stories »
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
